PL3236960T3 - Fluralaner do zastosowania w leczeniu demodekozy - Google Patents
Fluralaner do zastosowania w leczeniu demodekozyInfo
- Publication number
- PL3236960T3 PL3236960T3 PL15817303.9T PL15817303T PL3236960T3 PL 3236960 T3 PL3236960 T3 PL 3236960T3 PL 15817303 T PL15817303 T PL 15817303T PL 3236960 T3 PL3236960 T3 PL 3236960T3
- Authority
- PL
- Poland
- Prior art keywords
- demodicosis
- fluralaner
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14199562 | 2014-12-22 | ||
| PCT/EP2015/080744 WO2016102437A1 (en) | 2014-12-22 | 2015-12-21 | Use of isoxazoline compounds for treating demodicosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3236960T3 true PL3236960T3 (pl) | 2025-07-07 |
Family
ID=52146273
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15817303.9T PL3236960T3 (pl) | 2014-12-22 | 2015-12-21 | Fluralaner do zastosowania w leczeniu demodekozy |
| PL21213190.8T PL4008329T3 (pl) | 2014-12-22 | 2015-12-21 | Związki izoksazoliny do zastosowania w leczeniu demodekozy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21213190.8T PL4008329T3 (pl) | 2014-12-22 | 2015-12-21 | Związki izoksazoliny do zastosowania w leczeniu demodekozy |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20170348286A1 (enExample) |
| EP (3) | EP4599830A3 (enExample) |
| JP (1) | JP6706262B2 (enExample) |
| CN (2) | CN114681453A (enExample) |
| AU (3) | AU2015371175B2 (enExample) |
| BR (1) | BR112017013286A2 (enExample) |
| CA (1) | CA2971296A1 (enExample) |
| DK (2) | DK4008329T3 (enExample) |
| ES (2) | ES3037078T3 (enExample) |
| FI (2) | FI3236960T3 (enExample) |
| PL (2) | PL3236960T3 (enExample) |
| PT (2) | PT4008329T (enExample) |
| RU (1) | RU2709198C2 (enExample) |
| WO (1) | WO2016102437A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016022066A1 (en) | 2014-08-04 | 2016-02-11 | Jerry Tan Eye Surgery Pte Ltd | Pharmaceutical compositions for demodex related blepharitis and eyelid crusting |
| BR112017013286A2 (pt) | 2014-12-22 | 2018-03-06 | Intervet International B.V. | composto de isoxazolina, e, uso de um composto de isoxazolina. |
| WO2018039508A1 (en) * | 2016-08-25 | 2018-03-01 | Merial, Inc. | Method for reducing unwanted effects in parasiticidal treatments |
| CN107501199A (zh) * | 2017-08-16 | 2017-12-22 | 南京农业大学 | 氟雷拉纳单体化合物的提取和纯化方法 |
| AU2018385766B2 (en) | 2017-12-15 | 2022-12-01 | Tarsus Pharmaceuticals, Inc. | Isoxazoline parasiticide formulations and methods for treating blepharitis |
| US12502377B2 (en) | 2019-04-04 | 2025-12-23 | Tarsus Pharmaceuticals, Inc. | Method of eradicating ticks that attach to humans using lotilaner formulations |
| US11880349B2 (en) | 2019-04-30 | 2024-01-23 | Salesforce, Inc. | System or method to query or search a metadata driven distributed ledger or blockchain |
| BR112022012269A2 (pt) | 2019-12-18 | 2022-08-30 | Elanco Tiergesundheit Ag | Derivados de isoxazolina como pesticidas |
| CN116194450A (zh) | 2020-07-24 | 2023-05-30 | 礼蓝美国公司 | 用于制备异噁唑啉化合物及其中间体的工艺 |
| CN115785017B (zh) * | 2022-12-06 | 2023-12-08 | 海利尔药业集团股份有限公司 | 一种取代的苯酰胺异噁唑啉衍生物或其作为农药可接受的盐、组合物及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2067863C1 (ru) * | 1994-05-25 | 1996-10-20 | Казанский государственный технологический университет | Акарицидный состав для лечения чесотки домашних животных |
| KR101197482B1 (ko) | 2004-03-05 | 2012-11-09 | 닛산 가가쿠 고교 가부시키 가이샤 | 이속사졸린 치환 벤즈아미드 화합물 및 유해생물 방제제 |
| DE102004053964A1 (de) * | 2004-11-09 | 2006-05-11 | Bayer Healthcare Ag | Mittel gegen Demodikose |
| TWI412322B (zh) | 2005-12-30 | 2013-10-21 | Du Pont | 控制無脊椎害蟲之異唑啉 |
| TWI430995B (zh) | 2007-06-26 | 2014-03-21 | Du Pont | 萘異唑啉無脊椎有害動物控制劑 |
| CA2971008A1 (en) | 2007-06-27 | 2008-12-31 | E. I. Du Pont De Nemours And Company | Animal pest control method |
| TWI556741B (zh) * | 2007-08-17 | 2016-11-11 | 英特威特國際股份有限公司 | 異唑啉組成物及其作為抗寄生蟲藥上的應用 |
| TWI411395B (zh) | 2007-12-24 | 2013-10-11 | Syngenta Participations Ag | 殺蟲化合物 |
| WO2010079077A1 (en) | 2008-12-18 | 2010-07-15 | Novartis Ag | Isoxazolines derivatives and their use as pesticide |
| WO2010070068A2 (en) * | 2008-12-19 | 2010-06-24 | Novartis Ag | Organic compounds |
| WO2012089623A1 (en) | 2010-12-27 | 2012-07-05 | Intervet International B.V. | Topical localized isoxazoline formulation comprising glycofurol |
| FI2658542T4 (fi) | 2010-12-27 | 2025-09-02 | Intervet Int Bv | Paikallisesti rajoitetulle alueelle käytettävä isoksatsoliiniformulaatio |
| HRP20160601T1 (hr) * | 2011-03-10 | 2016-07-01 | Zoetis Services Llc | Spirociklički derivati izoksazolina kao antiparazitska sredstva |
| TWI567064B (zh) | 2011-09-12 | 2017-01-21 | 龍馬躍有限公司 | 包含異唑啉活性劑之殺寄生蟲組合物、方法及其用途 |
| MD4577C1 (ro) | 2012-02-06 | 2019-02-28 | Merial Inc. | Compoziţii masticabile de uz veterinar care conţin agent activ izoxazolinic şi utilizarea acestora în tratamentul sau prevenirea unei infestări sau infecţii parazitare |
| RU2632965C2 (ru) | 2012-04-04 | 2017-10-11 | Интервет Интернэшнл Б.В. | Мягкие жевательные фармацевтические продукты |
| WO2014090918A1 (en) * | 2012-12-13 | 2014-06-19 | Novartis Ag | Process for the enantiomeric enrichment of diaryloxazoline derivatives |
| MX373872B (es) * | 2013-12-20 | 2020-03-26 | Intervet Int Bv | Composiciones de isoxazolina y uso de las mismas en la prevención o tratamiento de infestaciones parasitarias en animales. |
| BR112017013286A2 (pt) | 2014-12-22 | 2018-03-06 | Intervet International B.V. | composto de isoxazolina, e, uso de um composto de isoxazolina. |
-
2015
- 2015-12-21 BR BR112017013286-9A patent/BR112017013286A2/pt not_active Application Discontinuation
- 2015-12-21 FI FIEP15817303.9T patent/FI3236960T3/fi active
- 2015-12-21 ES ES21213190T patent/ES3037078T3/es active Active
- 2015-12-21 WO PCT/EP2015/080744 patent/WO2016102437A1/en not_active Ceased
- 2015-12-21 DK DK21213190.8T patent/DK4008329T3/da active
- 2015-12-21 FI FIEP21213190.8T patent/FI4008329T3/fi active
- 2015-12-21 DK DK15817303.9T patent/DK3236960T3/da active
- 2015-12-21 PT PT212131908T patent/PT4008329T/pt unknown
- 2015-12-21 ES ES15817303T patent/ES3018234T3/es active Active
- 2015-12-21 CN CN202210404756.7A patent/CN114681453A/zh active Pending
- 2015-12-21 CN CN201580069964.4A patent/CN106999475B/zh active Active
- 2015-12-21 PT PT158173039T patent/PT3236960T/pt unknown
- 2015-12-21 EP EP25179725.4A patent/EP4599830A3/en active Pending
- 2015-12-21 RU RU2017126029A patent/RU2709198C2/ru active
- 2015-12-21 PL PL15817303.9T patent/PL3236960T3/pl unknown
- 2015-12-21 US US15/537,547 patent/US20170348286A1/en not_active Abandoned
- 2015-12-21 PL PL21213190.8T patent/PL4008329T3/pl unknown
- 2015-12-21 EP EP15817303.9A patent/EP3236960B1/en active Active
- 2015-12-21 EP EP21213190.8A patent/EP4008329B1/en active Active
- 2015-12-21 JP JP2017533378A patent/JP6706262B2/ja active Active
- 2015-12-21 AU AU2015371175A patent/AU2015371175B2/en active Active
- 2015-12-21 CA CA2971296A patent/CA2971296A1/en active Pending
-
2018
- 2018-04-04 US US15/944,967 patent/US10799483B2/en active Active
-
2020
- 2020-09-09 US US17/015,263 patent/US20200405692A1/en not_active Abandoned
-
2021
- 2021-06-04 AU AU2021203686A patent/AU2021203686A1/en not_active Abandoned
-
2023
- 2023-08-25 AU AU2023219972A patent/AU2023219972B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283086A (en) | Use of cannabidiol in the treatment of tuberous sclerosis complex | |
| IL281793A (en) | Use of cannabinoids in the treatment of epilepsy | |
| PL3157512T3 (pl) | Zastosowanie kannabidioli w leczeniu padaczki | |
| DK3590543T3 (da) | Medicinsk forbinding | |
| IL249292A0 (en) | Methods and devices for treating pulmonary edema | |
| EP3205103C0 (en) | INTER AND INTRA UNIFICATION BLOCK COPY | |
| HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
| DK3231444T3 (da) | Ny behandling | |
| PL3503890T3 (pl) | Stosowanie pridopidyny w leczeniu dystonii | |
| EP3215219C0 (en) | SKIN TREATMENT SYSTEM | |
| HUE050944T2 (hu) | Kezelési eljárás tradipitant alkalmazásával | |
| HRP20182134T1 (hr) | Triazinski spoj i njegova upotreba u medicinske svrhe | |
| PL3236960T3 (pl) | Fluralaner do zastosowania w leczeniu demodekozy | |
| DK3302519T3 (da) | Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom | |
| IL251904A0 (en) | Apilimod for use in the treatment of melanoma | |
| PL3194421T3 (pl) | Związki cytotoksyczne i przeciwmitotyczne oraz sposoby ich wykorzystania | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
| PT3134119T (pt) | Tratamento do cancro | |
| HUE046894T2 (hu) | Anamorelinen alapuló gyógyászati kezelések | |
| DK3302478T3 (da) | Pac-1 kombinations behandling | |
| IL251345A0 (en) | Compositions for use in the treatment of peri-implantitis | |
| DK3125874T3 (da) | Et terapeutisk middel til anvendelse i behandlingen af infektioner | |
| PL3373922T3 (pl) | Kompozycje i sposoby do stosowania do leczenia homocystynurii | |
| HUE046209T2 (hu) | Kompozíció porckoronggal összefüggõ fájdalom kezelésében történõ alkalmazásra | |
| DE112015001144A5 (de) | Therapievorrichtung |